Welcome Mr. Lukasz from the investor Mekong Capital to visit the Spobiotic Research Center.

On September 21, 2024, the ANABIO Spobiotic Research Center (ANABIO R&D) had the honor of welcoming Mr. Lukasz – an investor from Mekong Capital – to visit its Center.

During the visit, Mr. Lukasz was briefed by the R&D specialists at the Center on the research and development processes, as well as the outstanding efficacy of the probiotic products currently in development. These results, validated through clinical trials, not only confirm the quality of the products but also stand as evidence of the company’s commitment to delivering breakthrough, reliable health solutions.

Mr. Lukasz highly appreciated the efforts and achievements of the Center’s staff, and expressed strong confidence in the company’s potential to shape the probiotic market in Vietnam. He also offered strategic recommendations for upgrading infrastructure and expanding the research center to position the company as an internationally recognized biotech enterprise. According to Mr. Lukasz, with its bold direction and long-term vision, the company has the potential to become a “tech unicorn” – directly competing with the world’s leading bioproduct corporations. Mr. Lukasz’s visit underscores the company’s growing appeal on the international stage and provides strong motivation for continued investment in research and development. This support reinforces the company’s mission to elevate the LiveSpo brand of probiotics globally, accompanying consumers worldwide on their journey toward comprehensive health protection

Here are a few images from the visit:

Dr. Nguyen Hoa Anh, Director of ANABIO R&D Co., Ltd., welcomes Mr. Lukasz.
Mr. Lukasz visits the Central Laboratory.

The latest discovery in research on the effects of Bacillus clausii probiotic spores (LiveSpo CLAUSY) has just been published in the prestigious international journal Scientific Reports-Nature.

The research team at the National Children’s Hospital and the Spobiotic Research Center of ANABIO R&D has published impressive results on the effectiveness of liquid Bacillus clausii spores (LiveSpo CLAUSY, Bacillus clausii concentration ≥ 2 billion/5 mL vial) in supporting the treatment of prolonged diarrhea in children.

This clinical trial marks a significant advancement in understanding and treating pediatric diarrhea. The probiotic product LiveSpo CLAUSY is not only safe for children but also shortens the treatment duration by 2-3 days and enhances effectiveness by up to 50-60%, depending on specific symptoms. Notably, the product can reduce the excessive secretion of pro-inflammatory cytokines by up to 29%, a key factor in reducing inflammation and restoring the intestinal mucosa.

This breakthrough brings new hope for children suffering from prolonged diarrhea and opens up promising prospects for research and treatment of other gastrointestinal diseases.

Hosted By Wordpress Clusters